Areas of interest

• Norditropin authorized indications [GHD/AGHD/SGA/Turner syndrome/PWS/ NS/ISS]
• Early initiation of treatment, treatment optimisation
• Prediction of growth during GH therapy
• Epidemiology of approved conditions
• HEOR/PRO/QoL studies
• Devices
• Adherence/persistence in GHT
• Genetics of growth and growth disorders, growth charts
• Short stature in rare or undefined genetic disorders or syndromes
• Synergistic use (GH + other products)
• MASH in AGHD/GHD
• New disease areas: Acromegaly, CAH, Achondroplasia, XLH, HypoPTH (natural history, chart reviews)
• Other Protocols not in conflict or redundant with NNI research/scientific commitment in the thereaputic area

Areas not in scope

• Studies that overlap with completed, ongoing or planned research
• Burns anti-ageing, and sports performance enhancement
• Request for placebo only

Areas of interest

• Somapacitan authorized indications –AGHD
• Adherence/Persistence/treatment initiation
• Traumatic Brain Injury
• Metabolic outcomes (e.g., lipid metabolism)
• Impact on Liver function / hepatic fat (e.g., AGHD with MAFLD/MASH comorbidity)
• Switching from daily GH; switching between Long-acting growth hormone brands
• Combination treatment somapacitan & GLP-1
• Titration and Insulin-like growth factor -1 (IGF-I) excursions
• Health Economic outcomes (e.g., work productivity), PRO/QoL
• Transition GHD to adulthood
• Other protocols not in conflict or redundant with NNI research/scientific commitment in the therapeutic area

Areas not in scope

• Studies that overlap with completed, ongoing or planned research
• Abuse (i.e., anti-ageing, doping)
• Request for placebo only

Areas of interest

• Somapacitan authorised indications – GHD where approved
• Somapacitan use in children with GHD below 2.5 years
• Use in paediatric Prader-Willi patients 
• Adherence/persistence/treatment initiation
• Prediction of growth during somapacitan therapy 
• Metabolic outcomes (e.g., lipid metabolism)
• Impact on body composition
• Switching from daily GH 
• Switching from weekly GH
• Impact on energy levels, QoL
• Transition GHD to adulthood quality of life
• Endocrine sequalae in cancer survivor and long-acting growth hormone use
• Other protocols not in conflict or redundant with NNI research/scientific commitment in the therapeutic area

Areas not in scope

• Studies that overlap with completed, ongoing or planned research
• General off-label use in non-short stature patients
• Use in paediatric non-replacement indications currently under clinical investigation in the REAL program
• Abuse (i.e., anti-ageing, doping)
• Request for placebo only